CJC No DAC is commonly used shorthand for CJC-1295 without DAC, more accurately aligned with Mod GRF 1-29 (a stabilized GHRH(1-29) analog). In research discussions it is used to increase growth hormone (GH) pulsatility, especially when paired with a GHRP such as ipamorelin.
Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration.
Typical daily range: 100–300 mcg once daily (gradual titration).
Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.
Storage: Lyophilized: refrigerate at 2–8 °C; reconstituted: refrigerate and use within 1–2 weeks.
Schedule: Daily subcutaneous injections for 8–12 weeks.
Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Goal: Stimulate pulsatile GH release and elevate IGF-1 levels to support body composition, recovery, and overall metabolic health.
Frequency: Inject once daily subcutaneously, typically at bedtime to align with natural nocturnal GH pulsatility.
| Phase | Dose | Syringe (U-100) |
|---|---|---|
| Weeks 1–2 | 100 mcg | 6 units (0.06 mL) |
| Weeks 3–4 | 150 mcg | 9 units (0.09 mL) |
| Weeks 5–6 | 200 mcg | 12 units (0.12 mL) |
| Weeks 7–12 | 250–300 mcg | 15–18 units (0.15–0.18 mL) |
Endogenous growth hormone–releasing hormone (GHRH) from the hypothalamus stimulates pituitary somatotrophs to release GH in pulses. Mod GRF 1-29 is a modified fragment of GHRH designed to resist enzymatic degradation, often discussed in research communities for short-acting, pulse-supportive GH release.
- Enhanced GH pulse signaling (mechanistic rationale; depends on timing/food/sleep).
- Synergy with GHRPs (e.g., ipamorelin) for larger GH pulses.
- IGF-1 downstream signaling may increase over time depending on exposure and individual response.
Mod GRF 1-29 binds the GHRH receptor on pituitary somatotrophs, activating cAMP signaling and promoting GH secretion. In gut–brain axis terms, it’s primarily a neuroendocrine peptide (hypothalamus → pituitary), but peripheral metabolic state (glucose/insulin, free fatty acids) can influence GH secretion and somatostatin tone.
- Injection site irritation (if injected).
- Flushing, headache (reported with some GHRH analogs).
- Water retention, tingling (possible GH-axis related effects).
- Potential effects on glucose handling with prolonged GH-axis manipulation (context-dependent).
- Pregnancy/breastfeeding (insufficient data).
- Active malignancy or history of cancer (GH/IGF axis theoretical concern).
- Uncontrolled diabetes/metabolic disease (monitoring complexity).
In research settings, Mod GRF 1-29 is most commonly administered SubQ. IM is less common and not clearly superior for short-acting microgram dosing.
- Ipamorelin: classic pairing to increase GH pulse amplitude (GHRH + GHRP synergy).
- Sleep support: GH pulses are strongly tied to sleep quality/architecture.
- Keep stacks simple; adding insulin sensitizers, thyroid agents, etc. increases confounders and risk.
- Seminal discovery of GHRH and endocrine function. Science. 1982. PMID: 6122015
- GHRH receptor and pituitary GH secretion physiology (review). Endocr Rev. 1999. PMID: 10337570
- Modified GRF (1-29) analogs and GH release in humans (pharmacology). J Clin Endocrinol Metab. 1995. PMID: 7714089
- GHRH and somatostatin interplay controlling GH pulsatility. Endocr Rev. 2000. PMID: 11041429
- GHRP + GHRH synergy in GH secretion (human endocrine study). J Clin Endocrinol Metab. 1994. PMID: 8175955
- Clinical evaluation of CJC-1295 (with DAC) and GH/IGF-1 elevation (context for naming confusion). J Clin Endocrinol Metab. 2006. PMID: 16492687